Alemtuzumab Based RIC HSCT with Pre Emptive DLI as An Effective Strategy to Achieve Long Term Disease Remission In Patients with High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML)

Shreyans A. Gandhi; Victoria T. Potter; Victoria J. Tindell; Rachel Kesse Adu; Laura Reiff Zall; Michelle Kenyon; Judith C. W. Marsh; Aloysius Y. Ho; Ghulam J. Mufti; Antonio Pagliuca; ZiYi Lim

Alemtuzumab Based RIC HSCT with Pre Emptive DLI as An Effective Strategy to Achieve Long Term Disease Remission In Patients with High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML)

Shreyans A. Gandhi, Victoria T. Potter, Victoria J. Tindell, Rachel Kesse Adu, Laura Reiff Zall, Michelle Kenyon, Judith C. W. Marsh, Aloysius Y. Ho, Ghulam J. Mufti, Antonio Pagliuca, ZiYi Lim

King's College Hospital

Research output: Contribution to journal › Meeting abstract

Original language	English
Pages (from-to)	558 - 559
Number of pages	2
Journal	Blood
Volume	116
Issue number	21
Publication status	Published - 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Gandhi, S. A., Potter, V. T., Tindell, V. J., Adu, R. K., Zall, L. R., Kenyon, M., Marsh, J. C. W., Ho, A. Y., Mufti, G. J., Pagliuca, A., & Lim, Z. (2010). Alemtuzumab Based RIC HSCT with Pre Emptive DLI as An Effective Strategy to Achieve Long Term Disease Remission In Patients with High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML). Blood, 116(21), 558 - 559.

@article{195337b57c4c45a4ae3b9b8cd968933c,

title = "Alemtuzumab Based RIC HSCT with Pre Emptive DLI as An Effective Strategy to Achieve Long Term Disease Remission In Patients with High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML)",

author = "Gandhi, {Shreyans A.} and Potter, {Victoria T.} and Tindell, {Victoria J.} and Adu, {Rachel Kesse} and Zall, {Laura Reiff} and Michelle Kenyon and Marsh, {Judith C. W.} and Ho, {Aloysius Y.} and Mufti, {Ghulam J.} and Antonio Pagliuca and ZiYi Lim",

year = "2010",

language = "English",

volume = "116",

pages = "558 -- 559",

journal = "Blood",

issn = "1528-0020",

publisher = "American Society of Hematology",

number = "21",

}

Gandhi, SA, Potter, VT, Tindell, VJ, Adu, RK, Zall, LR, Kenyon, M, Marsh, JCW, Ho, AY, Mufti, GJ, Pagliuca, A & Lim, Z 2010, 'Alemtuzumab Based RIC HSCT with Pre Emptive DLI as An Effective Strategy to Achieve Long Term Disease Remission In Patients with High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML)', Blood, vol. 116, no. 21, pp. 558 - 559.

Alemtuzumab Based RIC HSCT with Pre Emptive DLI as An Effective Strategy to Achieve Long Term Disease Remission In Patients with High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML). / Gandhi, Shreyans A.; Potter, Victoria T.; Tindell, Victoria J. et al.
In: Blood, Vol. 116, No. 21, 2010, p. 558 - 559.

Research output: Contribution to journal › Meeting abstract

TY - JOUR

T1 - Alemtuzumab Based RIC HSCT with Pre Emptive DLI as An Effective Strategy to Achieve Long Term Disease Remission In Patients with High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML)

AU - Gandhi, Shreyans A.

AU - Potter, Victoria T.

AU - Tindell, Victoria J.

AU - Adu, Rachel Kesse

AU - Zall, Laura Reiff

AU - Kenyon, Michelle

AU - Marsh, Judith C. W.

AU - Ho, Aloysius Y.

AU - Mufti, Ghulam J.

AU - Pagliuca, Antonio

AU - Lim, ZiYi

PY - 2010

Y1 - 2010

M3 - Meeting abstract

SN - 1528-0020

VL - 116

SP - 558

EP - 559

JO - Blood

JF - Blood

IS - 21

ER -